FDA Clearance Tracker · P030002-S028
TRULIGN TORIC POSTER CHAMBER INTRAOCULAR LENS
Last checked: Nov 20, 2026Latest source record: Jun 27, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Jun 27, 2014
Approved
Time to decision
374 days
Received Jun 18, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P030002-S028
- Device name
- TRULIGN TORIC POSTER CHAMBER INTRAOCULAR LENS
- Applicant
- Bausch & Lomb, Inc.
- Applicant location
- Irvine, CA
- Received
- Jun 18, 2013
- Decided
- Jun 27, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol - OSB
- Original approval
- P030002
Device type
- Device type
- LENS, INTRAOCULAR, TORIC OPTICS (MJP)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL OF THE POST-APPROVAL STUDY PROTOCOL.
Source documents
Other decisions for Bausch & Lomb, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Bausch + Lomb Multifocal for Astigmatism (kalifilcon A) One-Day Soft (hydrophilic) Contact Lens510(k)
K262941 · Decided Oct 16, 2026 · 56 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
P240005 · Decided Oct 10, 2024 · 216 days after receipt
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
K192005 · Decided Oct 4, 2019 · 67 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.